|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
In situ hybridization experiments were performed on tissue sections of normal breast and tumors with a high level of FGFR1 expression.
|
7927944 |
1994 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Endothelial cells of capillaries and larger vessels within the tumor were devoid of FGFR1 immunoreactivity.
|
8168112 |
1994 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
FGFR1, FGFR2 and FGFR4 were expressed at high levels in respectively 22%, 4% and 32% of tumors.FGFR3 expression was not detected.
|
7705943 |
1995 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
To determine whether bFGF and FGFR-1 are also required for tumor formation in these cells, liposome-mediated gene transfer was used to deliver episomal vectors containing antisense-oriented bFGF or FGFR-1 cDNAs into human melanomas, grown as subcutaneous tumors in nude mice.
|
9256280 |
1997 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Although all tumors expressed FGFR-1 I, 1 tumor did not express FGFR-1 K, suggesting the production of only a secretable form of FGFR-1 by this tumor.
|
9100589 |
1997 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
From 30 to 40% of the tumors presenting this amplification show concomitant amplification at the FGFR1 locus in 8p12.
|
9669664 |
1998 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
However, expression of Tiel and VEGFR-2 mRNA by the tumor vasculature in select stage IA-IIB patients, and FGFR-1 mRNA expression by the tumor cells in the same clinical stages was found.
|
10541167 |
1999 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Genetic analysis demonstrated positive FGFR 1 and less FGFR 2 mRNA in the tumor tissue, and FGFR 1 mRNA was beta type dominant.
|
11519853 |
2001 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Both amplifications and deletions of RAF1 and FGFR1 were significantly associated with high tumor grade (P < 0.0001), advanced stage (P < 0.0001), and poor survival (P < 0.05) if tumors of all of the stages where analyzed together.
|
11389083 |
2001 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
The investigations presented in this study document that inhibiting expression of bFGF or FGFR-1 in only the melanoma cells is as effective in blocking tumor growth as simultaneously inhibiting bFGF or FGFR-1 synthesis in the melanoma cells and the melanoma cell-interspersing vasculature.
|
12080186 |
2002 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
In vivo, tumor formation in nude mice was dramatically enhanced with FGFR-1 IIIc transfected (20 of 20) in comparison with sham transfected (0 of 10) cells.
|
12105858 |
2002 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Anti-tumor angiogenesis therapy using soluble receptors: enhanced inhibition of tumor growth when soluble fibroblast growth factor receptor-1 is used with soluble vascular endothelial growth factor receptor.
|
12136423 |
2002 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Inhibition of FGFR-1 splicing or overexpression of FGFR-1alpha inhibits pancreatic adenocarcinoma cell growth in vivo and restores cytotoxic responses to chemotherapy, thereby suggesting the basis of rational interventional strategies for this devastating tumor.
|
12127120 |
2003 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Based on histological grading and immunohistochemical (IHC) assays, we found strong direct relationships between 80K-H and FGFR-1 (r = 0.49, p = 0.003) and tumor grade (r = 0.42, p = 0.006).
|
12841677 |
2003 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Although FGFR-1 dimerization achieved by AIdF-2 injection led to highly differentiated and smaller NBT-II tumors, no sign of reduction of tumor angiogenesis was observed, thus suggesting that endothelial cells are resistant to FGF.
|
15273729 |
2004 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
FGFR-1 and FGFR-3 were expressed in most well-differentiated tumor types.
|
15564323 |
2005 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Our data show that FGFR-1 is expressed in early hematopoietic/endothelial precursor cells, as well as in a subpool of endothelial cells in tumor vessels, and that it is critical for hematopoietic but not for vascular development.
|
15774903 |
2005 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Moreover, we have also shown that the disruption of FGFR1 expression by introducing of FGFR1 siRNA was effective in elevating FGFR3 expression and tumor suppressive activities.
|
15558020 |
2005 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Neutralizing FGFR1-specific antibody abrogates the physiologic and chemoprotective effects of FGF-2/FGFR1beta signaling and inhibits tumor growth in mice xenotransplanted with human AML.
|
16598308 |
2006 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Microscopic analysis of the xenograft tumors revealed a reduced Ki-67 labeling and a lower amount of tumor necrosis in FGFR1-IIIb-expressing tumors.
|
17363592 |
2007 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
However, FGFR1 over-expression was detected in all primary RMS tumors and cell lines tested.
|
17696196 |
2007 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
In this review, we provide in this review a critical assessment of CISH and FISH and the impact of the analysis of amplification of specific oncogenes (eg, HER2, EGFR, MYC, CCND1, and FGFR1) and deletion of tumor suppressor genes (eg, BRCA1 and BRCA2) on our understanding of breast cancer.
|
17640550 |
2007 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemical expression of bFGF and FGFR1 in tumors was confirmed by real-time polymerase chain reaction.
|
16949906 |
2007 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Combined translocation with ZNF198-FGFR1 gene fusion and deletion of potential tumor suppressors in a myeloproliferative disorder.
|
17321332 |
2007 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
For example, one tumor harbored a 350-kb high-level amplification centered on FGFR1 and three tumors showed regions of homozygous loss 109 to 216 kb in size involving the RB1 tumor suppressor gene only.
|
17699850 |
2007 |